#EuropeanJournalOfPediatrics Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria https://t.co/o3pdLqpDEV
Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria https://t.co/RNZ8lBDHoW
RT @ndanmontero: #bilastina, un antihistamínico de segunda generación, está aprobado en Europa para el tratamiento de la rinoconjuntivitis…
#bilastina, un antihistamínico de segunda generación, está aprobado en Europa para el tratamiento de la rinoconjuntivitis alérgica y la urticaria en adultos y niños mayores de 6 años
Eur J Pediatrics Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria https://t.co/86UIOTkeyw
RT @ContinuumAEP: #EuropeanJournalOfPediatrics Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoc…
Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria https://t.co/RNZ8lBDHoW
#EuropeanJournalOfPediatrics Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria https://t.co/o3pdLqpDEV